Our GBM orthotopic xenografts also confirmed that SON reduction in GSCs leads to depletion of PTBP1 as well as the well-known GBM stemness marker SOX2, suggesting targeting SON efficiently suppresses the tumorigenic ability of GSCs and inhibits tumor cells’ stemness in vivo. Here, SOX2 is linked to glioblastoma.